Crinetics Pharmaceuticals Inc

Crinetics insider sales: 30,000 shares sold in a day for tax purposes, not a confidence drop, yet still worth watching for future moves.

Insider sales at Crinetics reveal strategic trading plans, but not a confidence shift—monitor upcoming clinical milestones before investing.

Crinetics insider trading shows bullish confidence: CCO Kalofonos buys and sells shares, exercises options, boosting long‑term commitment amid a $350 m IPO, signaling growth potential in oncology and endocrine pipelines.